ACP
PGNX

Acuta Capital Partners’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Acuta Capital Partners’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-150,000
Closed -$1.42M – 83
2017
Q1 		$1.42M Buy
+150,000
New +$1.5M 0.34% 44

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Acuta Capital Partners's PGNX Position: Q2 2017 in Review

Acuta Capital Partners sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2017, closing a stake of 100,000 shares — an estimated $944K sold.

Acuta Capital Partners first reported a position in PGNX in Q1 2016 and held it in 4 quarters. The position peaked at $2.74M in Q3 2016. 152 funds tracked by Wall St. Rank hold PGNX as of Q2 2017.

  • Acuta Capital Partners reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2017 after selling out during the quarter.
  • Acuta Capital Partners sold 100,000 Progenics Pharmaceuticals Inc shares in Q2 2017, an estimated $944K.
  • Acuta Capital Partners first reported a position in Progenics Pharmaceuticals Inc in Q1 2016 and held it in 4 quarters.
  • Acuta Capital Partners's Progenics Pharmaceuticals Inc position peaked at $2.74M in Q3 2016.
  • 152 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2017.

Based on Acuta Capital Partners's 13F filing for Q2 2017, filed 14 Aug 2017.